{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:27:55Z","timestamp":1786678075884,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16303-9","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:16:01Z","timestamp":1780884961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacovigilance of carmustine: distinct neurotoxic and systemic safety signals identified in FAERS"],"prefix":"10.1186","volume":"26","author":[{"given":"Kaizhi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"16303_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijms.2014.04.018","volume":"368","author":"L Zhao","year":"2014","unstructured":"Zhao L, Li L, Xu J, Zhong R. Comparative investigation of the DNA inter-strand crosslinks induced by ACNU, BCNU, CCNU and FTMS using high-performance liquid chromatography\u2013electrospray ionization tandem mass spectrometry. Int J Mass Spectrom. 2014;368:30\u20136. https:\/\/doi.org\/10.1016\/j.ijms.2014.04.018.","journal-title":"Int J Mass Spectrom"},{"issue":"2","key":"16303_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nec.2012.01.004","volume":"23","author":"S Nagpal","year":"2012","unstructured":"Nagpal S. The role of BCNU polymer wafers (gliadel) in the treatment of malignant glioma. Neurosurg Clin N Am. 2012;23(2):289\u201395. https:\/\/doi.org\/10.1016\/j.nec.2012.01.004.","journal-title":"Neurosurg Clin N Am"},{"issue":"10","key":"16303_CR3","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1245\/s10434-008-0048-2","volume":"15","author":"FJ Attenello","year":"2008","unstructured":"Attenello FJ, Mukherjee D, Datoo G, et al. Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15(10):2887\u201393. https:\/\/doi.org\/10.1245\/s10434-008-0048-2.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"16303_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a010369","volume":"10","author":"D Przepiorka","year":"1999","unstructured":"Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999;10(5):527\u201332. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010369.","journal-title":"Ann Oncol"},{"issue":"4","key":"16303_CR5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.1990.8.4.648","volume":"8","author":"C Wheeler","year":"1990","unstructured":"Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma: a dose-finding study. J Clin Oncol. 1990;8(4):648\u201356. https:\/\/doi.org\/10.1200\/JCO.1990.8.4.648.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16303_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00520-016-3399-4","volume":"25","author":"S Perreault","year":"2017","unstructured":"Perreault S, Baker J, Medoff E, et al. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Support Care Cancer. 2017;25(1):205\u20138. https:\/\/doi.org\/10.1007\/s00520-016-3399-4.","journal-title":"Support Care Cancer"},{"key":"16303_CR7","doi-asserted-by":"publisher","unstructured":"Kitko CL, Gatwood K, Connelly J. Preparing the patient for HSCT: conditioning regimens and their scientific rationale. In: Brown VI, editor. Hematopoietic stem cell transplantation for the pediatric hematologist\/oncologist. Springer International Publishing; 2018. p. 139-174. https:\/\/doi.org\/10.1007\/978-3-319-63146-2_9.","DOI":"10.1007\/978-3-319-63146-2_9"},{"key":"16303_CR8","doi-asserted-by":"publisher","DOI":"10.25258\/ijddt.12.3.76","author":"A Mali","year":"2022","unstructured":"Mali A, Bhanwase A. Carmustine: promising drug for treatment of glioma. Int J Drug Deliv Technol. 2022. https:\/\/doi.org\/10.25258\/ijddt.12.3.76.","journal-title":"Int J Drug Deliv Technol"},{"issue":"7","key":"16303_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0006-2952(02)00878-X","volume":"63","author":"H Ueda-Kawamitsu","year":"2002","unstructured":"Ueda-Kawamitsu H, Lawson TA, Gwilt PR. In vitro pharmacokinetics and pharmacodynamics of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol. 2002;63(7):1209\u201318. https:\/\/doi.org\/10.1016\/S0006-2952(02)00878-X.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"16303_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10143-010-0280-7","volume":"33","author":"HC Bock","year":"2010","unstructured":"Bock HC, Puchner MJA, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev. 2010;33(4):441\u20139. https:\/\/doi.org\/10.1007\/s10143-010-0280-7.","journal-title":"Neurosurg Rev"},{"issue":"9","key":"16303_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2176\/nmc.oa.2021-0024","volume":"61","author":"R Nishikawa","year":"2021","unstructured":"Nishikawa R, Iwata H, Sakata Y, Muramoto K, Matsuoka T. Safety of gliadel implant for malignant glioma: report of postmarketing surveillance in Japan. Neurol Med Chir (Tokyo). 2021;61(9):536\u201348. https:\/\/doi.org\/10.2176\/nmc.oa.2021-0024.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"1","key":"16303_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11060-019-03266-0","volume":"145","author":"P Yerram","year":"2019","unstructured":"Yerram P, Reiss SN, Modelevsky L, Gavrilovic IT, Kaley T. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. J Neurooncol. 2019;145(1):57\u201363. https:\/\/doi.org\/10.1007\/s11060-019-03266-0.","journal-title":"J Neurooncol"},{"issue":"2","key":"16303_CR13","doi-asserted-by":"publisher","first-page":"e4052","DOI":"10.7759\/cureus.4052","volume":"11","author":"SN Dvorak","year":"2019","unstructured":"Dvorak SN, Kurniali PC. BCNU (bis-chloroethylnitrosourea, carmustine) toxicity presented as a large pleural effusion 60 days post autologous stem cell transplant for non-hodgkin lymphoma. Cureus. 2019;11(2):e4052. https:\/\/doi.org\/10.7759\/cureus.4052.","journal-title":"Cureus"},{"issue":"2","key":"16303_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.62225\/2583049X.2024.4.2.2729","volume":"4","author":"MS Badawi","year":"2024","unstructured":"Badawi MS. Protective role of quercetin on carmustine-induced lung toxicity in adult male albino rats. Int J Adv Multidisc Res Stud. 2024;4(2):1537\u201344. https:\/\/doi.org\/10.62225\/2583049X.2024.4.2.2729.","journal-title":"Int J Adv Multidisc Res Stud"},{"key":"16303_CR15","unstructured":"Effects of mulberry extract on the liver pathology and serum biochemical parameters in carmustine administrated rats - volkan ipek, burcu menekse balkan, muhammed enes inanc, oguzhan kaplan, orhan corum, sukru gungor, harun karaca, ayhan ata, 2022. https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JBR-210750. Accessed 14 Jul 2025."},{"key":"16303_CR16","unstructured":"Research C for DE and. FDA adverse event reporting system (FAERS) database. FDA; 2024. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers-database. Accessed 14 Jul 2025."},{"issue":"2","key":"16303_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317. https:\/\/doi.org\/10.2165\/00002018-199920020-00002.","journal-title":"Drug Saf"},{"issue":"8","key":"16303_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/life10080138","volume":"10","author":"G Park","year":"2020","unstructured":"Park G, Jung H, Heo SJ, Jung I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance. Life (Basel Switz). 2020;10(8):138. https:\/\/doi.org\/10.3390\/life10080138.","journal-title":"Life (Basel Switz)"},{"issue":"6","key":"16303_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001.","journal-title":"Drug Saf"},{"issue":"6","key":"16303_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Supplement_6","key":"16303_CR21","doi-asserted-by":"publisher","first-page":"vi14","DOI":"10.1093\/neuonc\/noz175.610","volume":"21","author":"I Shibahara","year":"2019","unstructured":"Shibahara I, Miyasaka K, Sato S, et al. Path-14. Immunohistochemical analysis of tumor associated macrophage induced after carmustine wafer implantation in human glioblastoma. Neuro-oncol. 2019;21(Supplement_6):vi14\u2013146. https:\/\/doi.org\/10.1093\/neuonc\/noz175.610.","journal-title":"Neuro-oncol"},{"key":"16303_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jocn.2021.01.037","volume":"86","author":"I Shibahara","year":"2021","unstructured":"Shibahara I, Miyasaka K, Sekiguchi A, et al. Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma. J Clin Neurosci. 2021;86:202\u201310. https:\/\/doi.org\/10.1016\/j.jocn.2021.01.037.","journal-title":"J Clin Neurosci"},{"issue":"5","key":"16303_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/brainsci12050567","volume":"12","author":"T Ohnishi","year":"2022","unstructured":"Ohnishi T, Yamashita D, Inoue A, Suehiro S, Ohue S, Kunieda T. Is interstitial chemotherapy with carmustine (BCNU) wafers effective against local recurrence of glioblastoma? A pharmacokinetic study by measurement of BCNU in the tumor resection cavity. Brain Sci. 2022;12(5):567. https:\/\/doi.org\/10.3390\/brainsci12050567.","journal-title":"Brain Sci"},{"key":"16303_CR24","doi-asserted-by":"publisher","first-page":"125657","DOI":"10.1016\/j.ijbiomac.2023.125657","volume":"246","author":"D Li","year":"2023","unstructured":"Li D, Wang X, Han K, et al. Hypoxia and CD44 receptors dual-targeted nano-micelles with AGT-inhibitory activity for the targeting delivery of carmustine. Int J Biol Macromol. 2023;246:125657. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125657.","journal-title":"Int J Biol Macromol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16303-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16303-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16303-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:46:18Z","timestamp":1786675578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16303-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16303"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16303-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent from the patients\/participants or patients\/participants\u2019 legal guardian\/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"978"}}